Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations

References

• Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med.186, 1689–1699 (1997).
   PubMed Web of Science ®Google Scholar
• Sesardic D. Regulatory considerations on new adjuvants and delivery systems. Vaccine24(Suppl. 2), S2–S7 (2006).
   PubMed Web of Science ®Google Scholar
• Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol.12, 456–463 (2000).
   PubMed Web of Science ®Google Scholar
• Pink JR, Kieny MP. 4th Meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization – Organisation Mondiale de la Sante Fondation Merieux, Annecy, France, 23–25, June 2003. Vaccine22, 2097–2102 (2004).
   PubMedGoogle Scholar
• O’Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm. Res.21, 1519–1530 (2004).
   PubMed Web of Science ®Google Scholar
• Kara J, Mach O, Cerna H. Replication of Rous sarcoma virus and the biosynthesis of the oncogenic subviral ribonucleoprotein particles (“virosomes”) in the mitochondria isolated from Rous sarcoma tissue. Biochem. Biophys. Res. Commun.44, 162–169 (1971).
   PubMed Web of Science ®Google Scholar
• Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet2, 899–901 (1975).
   PubMed Web of Science ®Google Scholar
• Morein B, Helenius A, Simons K, Pettersson R, Kaariainen L, Schirrmacher V. Effective subunit vaccines against an enveloped animal virus. Nature276, 715–718 (1978).
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods40, 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol.11, 438–444 (2003).
   PubMed Web of Science ®Google Scholar
• Kersten G, Hirschberg H. Antigen delivery systems. Expert Rev. Vaccines3, 453–462 (2004).
   PubMedGoogle Scholar
• Lamb RA and Krug RM. Orthomyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA 1487–1531 (2001).
   Google Scholar
• Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J.6, 2651–9 (1987).
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest.90, 2491–2495 (1992).
   PubMed Web of Science ®Google Scholar
• Cusi MG. Applications of influenza virosomes as a delivery system. Hum. Vaccin.2, 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev.57, 451–463 (2005).
   PubMed Web of Science ®Google Scholar
• Felnerova D, Viret JF, Gluck R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol.15, 518–529 (2004).
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener L, ter Veer W et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine21, 925–931 (2003).
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine23(Suppl. 1), S26–S38 (2005).
   PubMed Web of Science ®Google Scholar
• Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines2, 189–196 (2003).
   PubMedGoogle Scholar
• Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine21, 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• de Jonge J, Holtrop M, Wilschut J, Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther.13, 400–411 (2006).
   PubMed Web of Science ®Google Scholar
• Schoen P, Bron J,Wilschut J. Delivery of foreign substances to cells mediated by fusion-active reconstituted influenza virus envelopes (virosomes). J. Liposome Res.3, 767–792 (1993).
   Google Scholar
• Schoen P, Chonn A, Cullis PR, Wilschut J, Scherrer P. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther.6, 823–32 (1999).
   PubMed Web of Science ®Google Scholar
• Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine18, 1327–1333 (2000).
   PubMed Web of Science ®Google Scholar
• Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine20, 2287–2295 (2002).
   PubMed Web of Science ®Google Scholar
• Bungener L, Huckriede A, de Mare A, Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine23, 1232–1241 (2005).
   PubMed Web of Science ®Google Scholar
• de Jonge J, Schoen P, Ter veer W, Stegmann T, Wilschut J, Huckriede A. Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim. Biophys. Acta1758(4), 527–536 (2006).
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet344, 160–163 (1994).
   PubMed Web of Science ®Google Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine20(Suppl. 5), B17–B23 (2002).
   PubMed Web of Science ®Google Scholar
• Correale P, Cusi MG, Sabatino M et al. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer37, 2097–103 (2001).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Gluck R. Potential of DNA vaccines delivered by influenza virosomes. Vaccine18, 1435 (2000).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Terrosi C, Savellini GG, Di Genova G, Zurbriggen R, Correale P. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine22, 735–739 (2004).
   PubMed Web of Science ®Google Scholar
• Waelti ER, Gluck R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer77, 728–733 (1998).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Zurbriggen R, Correale P et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine20, 3436–42 (2002).
   PubMed Web of Science ®Google Scholar
• Schwaninger R, Waelti E, Zajac P, Wetterwald A, Mueller D, Gimmi CD. Virosomes as new carrier system for cancer vaccines. Cancer Immunol. Immunother.53, 1005–1017 (2004).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Gluck R. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine17, 1301–1305 (1999).
   PubMed Web of Science ®Google Scholar
• Adamina M, Guller U, Bracci L, Heberer M, Spagnoli GC, Schumacher R. Clinical applications of virosomes in cancer immunotherapy. Expert Opin. Biol. Ther.6, 1113–1121 (2006).
   PubMed Web of Science ®Google Scholar
• Liu X, Siegrist S, Amacker M, Zurbriggen R, Pluschke G, Seeberger PH. Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem. Biol.1, 161–164 (2006).
   PubMed Web of Science ®Google Scholar
• Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP. Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol.16, 3295–3305 (2005).
   PubMed Web of Science ®Google Scholar
• Waelti E, Wegmann N, Schwaninger R et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res.62, 437–44 (2002).
   PubMed Web of Science ®Google Scholar
• Amacker M, Engler O, Kammer AR et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol.17, 695–704 (2005).
   PubMed Web of Science ®Google Scholar
• Angel J, Chaperot L, Molens JP et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine25, 3913–3921 (2007).
   PubMed Web of Science ®Google Scholar
• Hunziker IP, Zurbriggen R, Glueck R et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol.38, 475–484 (2001).
   PubMed Web of Science ®Google Scholar
• Mueller MS, Renard A, Boato F et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun.71, 4749–4758 (2003).
   PubMed Web of Science ®Google Scholar
• Poltl-Frank F, Zurbriggen R, Helg A et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin. Exp. Immunol.117, 496–503 (1999).
   PubMed Web of Science ®Google Scholar
• Schumacher R, Amacker M, Neuhaus D et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26–35) peptide encapsulated into virosomes in vitro. Vaccine23, 5572–5582 (2005).
   PubMed Web of Science ®Google Scholar
• Westerfeld N, Zurbriggen R. Peptides delivered by immunostimulating reconstituted influenza virosomes. J. Pept. Sci.11, 707–712 (2005).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Amacker M, Kammer AR et al. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer’s disease. J. Mol. Neurosci.27, 157–166 (2005).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Novak-Hofer I, Seelig A, Gluck R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res.39, 3–18 (2000).
   PubMed Web of Science ®Google Scholar
• Kammer AR, Amacker M, Rasi S et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine https://doi.org/10.1016/j.vaccine.2007.07.052 doi:10.1016/j.vaccine.2007.07.052 (2007) (Epub ahead of print).
   Google Scholar
• Gluck R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther.4, 1139–1145 (2004).
   PubMed Web of Science ®Google Scholar
• International Organization for Standardization.Particle size analysis – photon correlation spectroscopy. International Standard13321, 1–21 (1996).
   Google Scholar
• Struck DK, Hoekstra D, Pagano RE. Use of resonance energy transfer to monitor membrane fusion. Biochemistry20, 4093–4099 (1981).
   PubMed Web of Science ®Google Scholar
• Blumenthal R, Gallo SA, Viard M, Raviv Y, Puri A. Fluorescent lipid probes in the study of viral membrane fusion. Chem. Phys. Lipids116, 39–55 (2002).
   PubMed Web of Science ®Google Scholar
• Smit JM, Waarts BL, Bittman R, Wilschut J. Liposomes as target membranes in the study of virus receptor interaction and membrane fusion. Methods Enzymol.372, 374–392 (2003).
   PubMed Web of Science ®Google Scholar
• Stegmann T, Nir S, Wilschut J. Membrane fusion activity of influenza virus. Effects of gangliosides and negatively charged phospholipids in target liposomes. Biochemistry28, 1698–704 (1989).
   PubMed Web of Science ®Google Scholar
• Stegmann T, Schoen P, Bron R et al. Evaluation of viral membrane fusion assays. Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay. Biochemistry32, 11330–11337 (1993).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Kalinke U, Althage A et al. The role of antibody concentration and avidity in antiviral protection. Science276, 2024–2027 (1997).
   PubMed Web of Science ®Google Scholar
• Justewicz DM, Doherty PC, Webster RG. The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin. J. Virol.69, 5414–5421 (1995).
   PubMed Web of Science ®Google Scholar
• Pfeiffer B, Peduzzi E, Moehle K et al. A virosome–mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed. Engl.42, 2368–2371 (2003).
   PubMed Web of Science ®Google Scholar
• Barton GM. Viral recognition by Toll-like receptors. Semin. Immunol.19, 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Schumacher R, Adamina M, Zurbriggen R et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine22, 714–723 (2004).
   PubMed Web of Science ®Google Scholar
• Brokstad KA, Cox RJ, Eriksson JC, Olofsson J, Jonsson R, Davidsson A. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand. J. Immunol.54, 243–247 (2001).
   PubMed Web of Science ®Google Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B et al. The effect of pre-existing immunity to antigens of adenovirus of the human serotype 5 on immune responses of nonhuman primates to vaccine regimens based on human or chimpanzee-derived adenovirus vectors. J. Virol.81, 6594–6604 (2007).
   PubMed Web of Science ®Google Scholar
• Sharpe S, Polyanskaya N, Dennis M et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol.82, 2215–2223 (2001).
   PubMed Web of Science ®Google Scholar
• van der Wielen M, Vertruyen A, Froesner G et al. Immunogenicity and sfatey of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1–16 years. Pediatr. Infect. Dis. J.26, 705–710 (2007).
   PubMed Web of Science ®Google Scholar
• Kursteiner O, Moser C, Lazar H, Durrer P. Inflexal V – the influenza vaccine with the lowest ovalbumin content. Vaccine24, 6632–6635 (2006).
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Stornaiuolo G, Precone DF, Amendola A, Zanetti AR. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine20(Suppl. 5), B33–B35 (2002).
   PubMed Web of Science ®Google Scholar
• Kanra G, Marchisio P, Feiterna-Sperling C et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr. Infect. Dis. J.23, 300–306 (2004).
   PubMed Web of Science ®Google Scholar
• Schaad UB, Buhlmann U, Burger R et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob. Agents Chemother.44, 1163–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Conne P, Gauthey L, Vernet P et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine15, 1675–1679 (1997).
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine20(Suppl. 5), B29–B32 (2002).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Lomagistro MM, Valassina M, Valensin PE, Gluck R. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine. Vaccine18, 2838–2842 (2000).
   PubMed Web of Science ®Google Scholar
• Gluck U, Gebbers JO, Gluck R. Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol.73, 7780–7786 (1999).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350, 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol.68, 489–493 (2002).
   PubMed Web of Science ®Google Scholar
• D’Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J. Travel Med.13, 78–83 (2006).
   PubMed Web of Science ®Google Scholar
• Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine14, 982–986 (1996).
   PubMed Web of Science ®Google Scholar
• Clarke PD, Adams P, Ibanez R, Herzog C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med. Infect. Dis.4, 313–318 (2006).
   PubMedGoogle Scholar
• Herrington DA, Clyde DF, Losonsky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature328, 257–259 (1987).
   PubMed Web of Science ®Google Scholar
• Kinyanjui SM, Conway DJ, Lanar DE, Marsh K. IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar. J.6, 82 (2007).
   PubMedGoogle Scholar
• Achtman AH, Bull PC, Stephens R, Langhorne J. Longevity of the immune response and memory to blood-stage malaria infection. Curr. Top. Microbiol. Immunol.297, 71–102 (2005).
   PubMed Web of Science ®Google Scholar